Legend Biotech Current Ratio 2019-2021 | LEGN

Current and historical current ratio for Legend Biotech (LEGN) from 2019 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Legend Biotech current ratio for the three months ending December 31, 2021 was 3.39.
Legend Biotech Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-12-31 $0.95B $0.28B 3.39
2021-09-30 $0.65B $0.28B 2.37
2021-06-30 $0.72B $0.26B 2.76
2021-03-31 $0.48B $0.15B 3.26
2020-12-31 $0.59B $0.16B 3.68
2020-09-30 $0.60B $0.12B 4.88
2020-06-30 $0.67B $0.12B 5.85
2020-03-31 $0.27B $0.11B 2.41
2019-12-31 $0.21B $0.13B 1.62
2019-09-30 $0.00B 0.00
2019-06-30 $0.00B 0.00
2019-03-31 $0.00B 0.00
2018-12-31 $0.33B $0.16B 2.05
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $6.572B $0.090B
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in Cayman Islands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00